PDF(Pubmed)
Abstract：
UNASSIGNED: Ovarian cancer (OC) is mostly diagnosed in advanced stages with high incidence-to-mortality rate. Nevertheless, some patients achieve long-term disease-free survival. However, the prognostic markers have not been well established.
UNASSIGNED: The primary objective of this study was to analyse the association of the suggested prognostic marker rs2185379 in PRDM1 with long-term survival in a large independent cohort of advanced OC patients.
UNASSIGNED: We genotyped 545 well-characterized advanced OC patients. All patients were tested for OC predisposition. The effect of PRDM1 rs2185379 and other monitored clinicopathological and genetic variables on survival were analysed.
UNASSIGNED: The univariate analysis revealed no significant effect of PRDM1 rs2185379 on survival whereas significantly worse prognosis was observed in postmenopausal patients (HR = 2.49; 95%CI 1.90-3.26; p= 4.14 × 10 - 11) with mortality linearly increasing with age (HR = 1.05 per year; 95%CI 1.04-1.07; p= 2 × 10 - 6), in patients diagnosed with non-high-grade serous OC (HR = 0.44; 95%CI 0.32-0.60; p= 1.95 × 10 - 7) and in patients carrying a gBRCA1 pathogenic variant (HR = 0.65; 95%CI 0.48-0.87; p= 4.53 × 10 - 3). The multivariate analysis interrogating the effect of PRDM1 rs2185379 with other significant prognostic factors revealed marginal association of PRDM1 rs2185379 with worse survival in postmenopausal women (HR = 1.54; 95%CI 1.01-2.38; p= 0.046).
UNASSIGNED: Unlike age at diagnosis, OC histology or gBRCA1 status, rs2185379 in PRDM1 is unlikely a marker of long-term survival in patients with advance OC.
UNASSIGNED: The primary objective of this study was to analyse the association of the suggested prognostic marker rs2185379 in PRDM1 with long-term survival in a large independent cohort of advanced OC patients.
UNASSIGNED: We genotyped 545 well-characterized advanced OC patients. All patients were tested for OC predisposition. The effect of PRDM1 rs2185379 and other monitored clinicopathological and genetic variables on survival were analysed.
UNASSIGNED: The univariate analysis revealed no significant effect of PRDM1 rs2185379 on survival whereas significantly worse prognosis was observed in postmenopausal patients (HR = 2.49; 95%CI 1.90-3.26; p= 4.14 × 10 - 11) with mortality linearly increasing with age (HR = 1.05 per year; 95%CI 1.04-1.07; p= 2 × 10 - 6), in patients diagnosed with non-high-grade serous OC (HR = 0.44; 95%CI 0.32-0.60; p= 1.95 × 10 - 7) and in patients carrying a gBRCA1 pathogenic variant (HR = 0.65; 95%CI 0.48-0.87; p= 4.53 × 10 - 3). The multivariate analysis interrogating the effect of PRDM1 rs2185379 with other significant prognostic factors revealed marginal association of PRDM1 rs2185379 with worse survival in postmenopausal women (HR = 1.54; 95%CI 1.01-2.38; p= 0.046).
UNASSIGNED: Unlike age at diagnosis, OC histology or gBRCA1 status, rs2185379 in PRDM1 is unlikely a marker of long-term survival in patients with advance OC.
摘要：
■卵巢癌（OC）大多诊断为晚期，发病率与死亡率高。然而，一些患者实现长期无病生存。然而,预后标志物尚未得到很好的确定。
■本研究的主要目的是分析PRDM1中推荐的预后标志物rs2185379与一个大型独立的晚期OC患者队列中的长期生存率的相关性。
■我们对545例特征良好的晚期OC患者进行了基因分型。对所有患者进行OC易感性测试。分析了PRDM1rs2185379和其他监测的临床病理和遗传变量对生存的影响。
■单因素分析显示，PRDM1rs2185379对生存率无显著影响，而绝经后患者的预后明显较差（HR=2.49；95CI1.90-3.26；p=4.14×10-11），死亡率随年龄呈线性增加（HR=每年1.05；95CI1.04-1.07；p=2×10-6），诊断为非高级别浆液性OC的患者(HR=0.44;95CI0.32-0.60;p=1.95×10-7)和携带gBRCA1致病变异体的患者(HR=0.65;95CI0.48-0.87;p=4.53×10-3)。研究PRDM1rs2185379与其他重要预后因素的影响的多变量分析显示，PRDM1rs2185379与绝经后妇女生存率较差的边缘关联(HR=1.54;95CI1.01-2.38;p=0.046)。
■与诊断时的年龄不同，OC组织学或gBRCA1状态，PRDM1中的rs2185379不太可能是晚期OC患者长期生存的标志。
■本研究的主要目的是分析PRDM1中推荐的预后标志物rs2185379与一个大型独立的晚期OC患者队列中的长期生存率的相关性。
■我们对545例特征良好的晚期OC患者进行了基因分型。对所有患者进行OC易感性测试。分析了PRDM1rs2185379和其他监测的临床病理和遗传变量对生存的影响。
■单因素分析显示，PRDM1rs2185379对生存率无显著影响，而绝经后患者的预后明显较差（HR=2.49；95CI1.90-3.26；p=4.14×10-11），死亡率随年龄呈线性增加（HR=每年1.05；95CI1.04-1.07；p=2×10-6），诊断为非高级别浆液性OC的患者(HR=0.44;95CI0.32-0.60;p=1.95×10-7)和携带gBRCA1致病变异体的患者(HR=0.65;95CI0.48-0.87;p=4.53×10-3)。研究PRDM1rs2185379与其他重要预后因素的影响的多变量分析显示，PRDM1rs2185379与绝经后妇女生存率较差的边缘关联(HR=1.54;95CI1.01-2.38;p=0.046)。
■与诊断时的年龄不同，OC组织学或gBRCA1状态，PRDM1中的rs2185379不太可能是晚期OC患者长期生存的标志。
